SCHEMBL6426697

SCHEMBL6426697

Nc1ccc2c(ccc3c2ccc2c4ccccc4ccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 3/20 0.64
ALDH1A1 P00352 6/20 0.62
HSD17B10 Q99714 4/20 0.62
CYP3A4 P08684 2/20 0.62
HIF1A Q16665 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
ALOX15 P16050 1/20 0.60
CASP1 P29466 1/20 0.60
CASP7 P55210 1/20 0.60
HBB P68871 1/20 0.60
CYP1B1 Q16678 2/20 0.58
PLAU P00749 1/20 0.55
CYP2A6 P11509 1/20 0.55
TSHR P16473 1/20 0.55
CYP1A2 P05177 2/20 0.50
CYP1A1 P04798 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
MAPT P10636 3/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138724 1.00 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL1527441 0.98 ALDH1A1 (0.65) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL15896244 0.91 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL15896247 0.91 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL8121539 0.88 ALDH1A1 (0.55) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL20407332 0.87 ALDH1A1 (0.58) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL1758257 0.86 ALDH1A1 (0.64) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL7832399 0.85 ALDH1A1 (0.56) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL2445157 0.85 ALDH1A1 (0.57) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A
SCHEMBL29031940 0.85 ALDH1A1 (0.72) HPRT1ALDH1A1HSD17B10CYP3A4HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274687-B1 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-01-05 EP disclosed
US-6703392-B2 OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT ACTELION PHARMACEUTICALS LTD. (CH) 2004-03-09 US disclosed
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2003-09-18 US disclosed
EP-1274687-A1 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2003-01-15 EP disclosed
WO-2001068609-A1 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176415-A1 1,2,3,4-tetrahydroisoquinoline derivatives HCRTR2, HCRTR1, NPY2R HPRT1 1259/4885ALDH1A1 1115/4885HSD17B10 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.